423 related articles for article (PubMed ID: 33752265)
61. Chimeric Antigen Receptors Based on Low Affinity Mutants of FcεRI Re-direct T Cell Specificity to Cells Expressing Membrane IgE.
Ward DE; Fay BL; Adejuwon A; Han H; Ma Z
Front Immunol; 2018; 9():2231. PubMed ID: 30364107
[TBL] [Abstract][Full Text] [Related]
62. CAR T cells for infection, autoimmunity and allotransplantation.
Maldini CR; Ellis GI; Riley JL
Nat Rev Immunol; 2018 Oct; 18(10):605-616. PubMed ID: 30046149
[TBL] [Abstract][Full Text] [Related]
63. Multi-dimensional glycan microarrays with glyco-macroligands.
Narla SN; Nie H; Li Y; Sun XL
Glycoconj J; 2015 Oct; 32(7):483-95. PubMed ID: 25957565
[TBL] [Abstract][Full Text] [Related]
64. Glycobiology of cellular expiry: Decrypting the role of glycan-lectin regulatory complex and therapeutic strategies focusing on cancer.
Kumar Das A; Ghosh N; Mandal A; Sil PC
Biochem Pharmacol; 2023 Jan; 207():115367. PubMed ID: 36481348
[TBL] [Abstract][Full Text] [Related]
65. Worms to the rescue: can worm glycans protect from autoimmune diseases?
Kuijk LM; van Die I
IUBMB Life; 2010 Apr; 62(4):303-12. PubMed ID: 20101628
[TBL] [Abstract][Full Text] [Related]
66. Nanoparticle-based approaches to immune tolerance for the treatment of autoimmune diseases.
Serra P; Santamaria P
Eur J Immunol; 2018 May; 48(5):751-756. PubMed ID: 29427438
[TBL] [Abstract][Full Text] [Related]
67. Thymic commitment of regulatory T cells is a pathway of TCR-dependent selection that isolates repertoires undergoing positive or negative selection.
Coutinho A; Caramalho I; Seixas E; Demengeot J
Curr Top Microbiol Immunol; 2005; 293():43-71. PubMed ID: 15981475
[TBL] [Abstract][Full Text] [Related]
68. Approaches to inducing antigen-specific immune tolerance in allergy and autoimmunity: Focus on antigen-presenting cells and extracellular vesicles.
Nazimek K; Bryniarski K
Scand J Immunol; 2020 Jun; 91(6):e12881. PubMed ID: 32243636
[TBL] [Abstract][Full Text] [Related]
69. Checkpoint Inhibitors: Applications for Autoimmunity.
Tocheva AS; Mor A
Curr Allergy Asthma Rep; 2017 Sep; 17(10):72. PubMed ID: 28956259
[TBL] [Abstract][Full Text] [Related]
70. JAK/STAT-Dependent Chimeric Antigen Receptor (CAR) Expression: A Design Benefiting From a Dual AND/OR Gate Aiming to Increase Specificity, Reduce Tumor Escape and Affect Tumor Microenvironment.
Khanali J; Azangou-Khyavy M; Boroomand-Saboor M; Ghasemi M; Niknejad H
Front Immunol; 2021; 12():638639. PubMed ID: 34177890
[TBL] [Abstract][Full Text] [Related]
71. Glyco-Dendrimers as Intradermal Anti-Tumor Vaccine Targeting Multiple Skin DC Subsets.
Duinkerken S; Horrevorts SK; Kalay H; Ambrosini M; Rutte L; de Gruijl TD; Garcia-Vallejo JJ; van Kooyk Y
Theranostics; 2019; 9(20):5797-5809. PubMed ID: 31534520
[TBL] [Abstract][Full Text] [Related]
72. Manipulation of the glycan-specific natural antibody repertoire for immunotherapy.
New JS; King RG; Kearney JF
Immunol Rev; 2016 Mar; 270(1):32-50. PubMed ID: 26864103
[TBL] [Abstract][Full Text] [Related]
73. Immune Cell Hacking: Challenges and Clinical Approaches to Create Smarter Generations of Chimeric Antigen Receptor T Cells.
Elahi R; Khosh E; Tahmasebi S; Esmaeilzadeh A
Front Immunol; 2018; 9():1717. PubMed ID: 30108584
[TBL] [Abstract][Full Text] [Related]
74. Recent progress in targeting the sialylated glycan-SIGLEC axis in cancer immunotherapy.
Yu Y; Peng W
Cancer Biol Med; 2023 May; 20(5):369-84. PubMed ID: 37133224
[TBL] [Abstract][Full Text] [Related]
75. Glycans in nanomedicine, impact and perspectives.
Sampaolesi S; Nicotra F; Russo L
Future Med Chem; 2019 Jan; 11(1):43-60. PubMed ID: 30526037
[TBL] [Abstract][Full Text] [Related]
76. Glycans as shapers of tumour microenvironment: A sweet driver of T-cell-mediated anti-tumour immune response.
Fernandes Â; Azevedo CM; Silva MC; Faria G; Dantas CS; Vicente MM; Pinho SS
Immunology; 2023 Feb; 168(2):217-232. PubMed ID: 35574724
[TBL] [Abstract][Full Text] [Related]
77. Lymphatic vessels, miRNAs, and CAR T cells in tumor immunology.
Jiang X
J Zhejiang Univ Sci B; 2020 Jan.; 21(1):1-2. PubMed ID: 31898438
[TBL] [Abstract][Full Text] [Related]
78. Targeting N-glycan cryptic sugar moieties for broad-spectrum virus neutralization: progress in identifying conserved molecular targets in viruses of distinct phylogenetic origins.
Wang D; Tang J; Tang J; Wang LX
Molecules; 2015 Mar; 20(3):4610-22. PubMed ID: 25774492
[TBL] [Abstract][Full Text] [Related]
79. Changes of IgG
Trzos S; Link-Lenczowski P; Sokołowski G; Pocheć E
Front Immunol; 2022; 13():841710. PubMed ID: 35370997
[TBL] [Abstract][Full Text] [Related]
80. CAR T cells: Building on the CD19 paradigm.
Globerson Levin A; Rivière I; Eshhar Z; Sadelain M
Eur J Immunol; 2021 Sep; 51(9):2151-2163. PubMed ID: 34196410
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
